Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck-Reference-Cited by-同舟云学术

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck

Published:2020-11-16 Issue:3 Volume:10 Page:41-47
ISSN:2411-4634
Container-title:Head and Neck Tumors (HNT)
language:
Short-container-title:Opuholi golovy i šei

Author:

Kostalanova Yu. V.¹,Ganina K. A.²^ORCID,Makhonin A. A.³^ORCID,Gabrielyan A. G.³^ORCID

Affiliation:

1. Samara Regional Clinical Oncology Dispensary

2. Samara State Medical University, Ministry of Health of Russia

3. Samara Regional Clinical Oncology Dispensary; Samara State Medical University, Ministry of Health of Russia

Abstract

The immune system plays a key role in the development and progression of head and neck squamous cell carcinoma. Understanding the dysregulation and blockage of the immune system of malignant tumors in this location can improve treatment outcomes. A special group is made up of patients who have a widespread process and relapse after chemotherapy with platinum drugs, because they have a very poor prognosis and limitations in the possibilities of further treatment. To date, the most important data relate to drugs acting on the PD-1 (programmed cell death protein 1)/PD-L1 (programmed death ligand 1) immune checkpoints, which are used by the tumor to block the immune system, which have allowed to increase the effectiveness of treatment. The article presents a clinical case demonstrating the effectiveness of the use of checkpoint inhibitors after the use of platinum preparations.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Otorhinolaryngology,Surgery

Reference36 articles.

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.

2. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9–22. DOI: 10.1038/nrc2982.

3. Hashibe M., Brennan P., Chuang S.C. et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18(2):541–50. DOI: 10.1158/1055-9965.EPI-08-0347.

4. Pan C., Issaeva N., Yarbrough W.G. HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis. Cancers Head Neck 2018;3:12. DOI: 10.1186/s41199-018-0039-3.

5. Gameiro S.F., Ghasemi F., Barrett J.W. et al. Treatment-naive HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV-counterparts that has implications for immunotherapy. Oncoimmunology 2018;7:e1498439. DOI: 10.1080/2162402x.2018.1498439.